Novel potent liposome agonists of triggering receptor expressed on myeloid cells 2 phenocopy antibody treatment in cells

• Published in: Glia 2022-12, Vol.70 (12), p.2290-2308
• Main Authors: Boudesco, Christophe, Nonneman, Annelies, Cinti, Alessandro, Picardi, Paola, Redaelli, Loredana, Swijsen, Sofie, Roewe, Julian, Reinhardt, Peter, Ibach, Melanie, Walter, Jochen, Pocock, Jennifer M., Ren, Yi, Driguez, Pierre‐Alexandre, Dargazanli, Gihad, Eyquem, Stephanie, Proto, Jonathan, Flores‐Morales, Amilcar, Pradier, Laurent
• Format: Article
• Language: English
• Subjects: agonist; Agonists; Alzheimer Disease - metabolism; Alzheimer's disease; Antibodies; Antibodies - metabolism; Apoptosis; Brain - metabolism; Cellular structure; Dimerization; Humans; Ligands; Lipids; Liposomes; Membrane Glycoproteins - immunology; Microglia - metabolism; Myeloid cells; Myeloid Cells - metabolism; Neurodegenerative diseases; Phagocytes; Phosphatidylserine; Phosphatidylserines - metabolism; Phospholipids; phosphoplipids; Receptors; Receptors, Immunologic - immunology; Selectivity; Stimulation; triggering receptor expressed on myeloid cells 2; Triggering Receptor Expressed on Myeloid Cells-1 - metabolism
• ISSN: 0894-1491; 1098-1136
• DOI: 10.1002/glia.24252

The receptor Triggering Receptor Expressed on Myeloid cells 2 (TREM2) is associated with several neurodegenerative diseases including Alzheimer's Disease and TREM2 stimulation represents a novel therapeutic opportunity. TREM2 can be activated by antibodies targeting the stalk region, most likely through receptor dimerization. Endogenous ligands of TREM2 are suggested to be negatively charged apoptotic bodies, mimicked by phosphatidylserine incorporated in liposomes and other polyanionic molecules likely binding to TREM2 IgV fold. However, there has been much discrepancy in the literature on the nature of phospholipids (PLs) that can activate TREM2 and on the stability of the corresponding liposomes over time. We describe optimized liposomes as robust agonists selective for TREM2 over TREM1 in cellular system. The detailed structure/activity relationship studies of lipid polar heads indicate that negatively charged lipid heads are required for activity and we identified the shortest maximally active PL sidechain. Optimized liposomes are active on both TREM2 common variant and TREM2 R47H mutant. Activity and selectivity were further confirmed in different native TREM2 expressing cell types including on integrated cellular responses such as stimulation of phagocytic activity. Such tool agonists will be useful in further studies of TREM2 biology in cellular systems alongside antibodies, and in the design of small molecule synthetic TREM2 agonists. Main Points Stable liposomes were designed as potent TREM2 agonists for cellular systems. Lipid structure TREM2‐activity relationship clarified literature discrepancies. Active on both TREM2 common variant and R47H mutant.